Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com   Business     Sanofi enters a strategic collaboration with Ablynx (Ghent, Belgium) to develop nanobody-based therapeutics focused on immune-mediated inflammatory diseases. Sanofi will gain access to certain Nanobodies in Ablynx's existing portfolio as well as to Ablynx's proprietary Nanobody platform with exclusive global rights to […]

Is 2017 set to be the year we see a CAR-T therapy approved? Let’s find out from the leaders in the field Sponsored by CAR-TCR Summit, organized by Hanson Wade |    Jul 18, 2017 8:00am           Using your body’s own cells, engineering them to target tumors and cure cancer sounds like something […]

    Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com   Drugs at clinical stage   The US FDA Oncologic Drugs Advisory Committee (ODAC), with a vote 10-0, recommends the approval of Novartis' CTL019 or tisagentlecleucel, an investigational chimeric antigen receptor T cell (CAR-T) therapy as a treatment of relapsed or refractory (r:r) pediatric and yound adult […]

Mergers, Acquisitions and Joint Ventures   Sanofi acquires Protein Sciences (Meriden, Connecticut, USA), a privately held vaccines biotechnology company, for $650 million, and will make an additional $100 million payment upon achievement of certain milestones. Protein Sciences platform is based on a recombinant insect virus-based expression technology, which was used to produce Flubok, the only […]

      Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com   Editor's Note   As of June 2017, the US FDA has already approved 23 new drugs surpassing 2016’s overall approval of 22. The US regulator has approved 12 new drugs in the first three months, more than any other first quarter in recent years. The […]

    Btobioinnovation.com       Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation, jcm@btobioinnovation.com       Editor’s Note     After a little more than four years in existence, the Editorial Board of BtoBioinnovation has decided to terminate the edition of the Biopharmaceutical Newsweek letter. We would like to thank the hundreds of subscribers and readers […]